Prescriber's Corner
Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma
Lindsay Shelledy, PharmD, and Danielle Roman, PharmD, BCOP
West Penn Allegheny Oncology Network, Pittsburgh, Pennsylvania
Danielle Roman, PharmD, BCOP, West Penn Allegheny Oncology Network, Allegheny Health Network Cancer Institute, 4815 Liberty Avenue, Suite 340, Pittsburgh, PA 15317. E-mail: droman@wpaon.org
J Adv Pract Oncol 2015;6:361–365 |
DOI: 10.6004/jadpro.2015.6.4.6 |
© 2015 Harborside Press®
For access to the full length article, please
sign in.
